



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Gogos, A;Ney, LJ;Seymour, N;Van Rheenen, TE;Felmingham, KL

Title:

Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link?

Date:

2019-11-01

Citation:

Gogos, A., Ney, L. J., Seymour, N., Van Rheenen, T. E. & Felmingham, K. L. (2019). Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link?. *British Journal of Pharmacology*, 176 (21), pp.4119-4135. <https://doi.org/10.1111/bph.14584>.

Persistent Link:

<https://hdl.handle.net/11343/285604>

BJP special issue – Review

Sex differences in schizophrenia, bipolar disorder and PTSD: Are gonadal hormones the link?

Andrea Gogos^{1*†}, Luke J. Ney^{2†}, Natasha Seymour^{1,3}, Tamsyn E. Van Rheenen^{4,5},
Kim L. Felmingham⁶

¹ The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia;

² School of Medicine (Psychology), University of Tasmania, Sandy Bay, TAS, Australia;

³ Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia;

⁴ Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia;

⁵ Centre for Mental Health, School of Health Sciences, Faculty of Health, Arts and Design, Swinburne University, Melbourne, VIC, Australia;

⁶ School of Psychological Sciences, The University of Melbourne, Parkville, VIC, Australia.

† Joint first author

*Corresponding Author:

Andrea Gogos

Florey Institute of Neuroscience and Mental Health

30 Royal Parade, Parkville VIC 3052

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1111/bph.14584](https://doi.org/10.1111/bph.14584)

Email: andrea.gogos@florey.edu.au

Ph: +613 9035 6798

Author Manuscript

Abstract

In this review, we describe the sex differences in prevalence, onset, symptom profiles and disease outcome that are evident in schizophrenia, bipolar disorder and post-traumatic stress disorder. Women with schizophrenia tend to exhibit less disease impairment than men; by contrast, women with post-traumatic stress disorder are more affected than men. The most likely candidates to explain these sex differences are gonadal hormones. This review details the clinical evidence that [estradiol](#) and [progesterone](#) are dysregulated in these psychiatric disorders. Notably, existing data on estradiol, and to a lesser extent, progesterone, suggest that low levels of these hormones may increase the risk of disease development and worsen symptom severity. We argue that future studies require a more inclusive, considered analysis of gonadal steroid hormones and the intricacies of the interactions between them, with methodological rigour applied, to enhance our understanding of the roles of steroid hormones in psychiatric disorders.

Keywords: schizophrenia; bipolar disorder (BD); posttraumatic stress disorder (PTSD); estradiol; progesterone

Abbreviations

BD: bipolar disorder

CNS: central nervous system

DHEA: dehydroepiandrosterone

HPA: hypothalamic-pituitary-adrenal

HPG: hypothalamic-pituitary-gonadal

PACAP: pituitary adenylate cyclase-activating peptide

PTSD: post-traumatic stress disorder

1. Introduction

Sex differences are prevalent in disorders affecting the central nervous system (CNS). Schizophrenia, bipolar disorder (BD), post-traumatic stress disorder (PTSD), major depressive disorder, autism spectrum disorder, Alzheimer's disease, multiple sclerosis, motor neuron disease and Parkinson's disease are examples of such conditions that report sexually dimorphic incidence rates, symptomology or prognosis (Christiansen *et al.*, 2015; Diflorio *et al.*, 2010; Gogos *et al.*, 2015; Pinares-Garcia *et al.*, 2018; Sanchez *et al.*, 2010). While there are a number of biological, cultural and environmental factors that may underlie these sex differences, the important role of gonadal steroid hormones has become increasingly evident in recent decades. Steroids have potent and widespread effects in the brain and the role of gonadal hormones have been of particular interest (Gogos *et al.*, 2015; Pinares-Garcia *et al.*, 2018). Accumulating evidence demonstrates the influence of gonadal steroid hormones on cognition and various pathophysiological pathways, in addition to their therapeutic potential. Throughout the lifespan, mammalian females experience various endogenous fluctuations in ovarian hormone levels, which can influence the symptom profile of CNS disorders. Such fluctuations include the recurring oscillations of [estradiol](#) and [progesterone](#) across the reproductive cycle (i.e. the menstrual cycle), the dramatic changes throughout pregnancy and post-partum that orchestrate reproduction, and the overall decline in circulating hormone levels associated with reproductive senescence (i.e. menopause) (Sbisa *et al.*, 2017; Sun *et al.*, 2016). Researchers have utilised these natural variations in estradiol and progesterone to investigate their effects on the expression of psychiatric disorders and subsequently glean insight into the mechanisms of endogenous gonadal hormones and how they may act in concert with each other. More recently, the impact of exogenous hormone administration has been investigated, highlighting their therapeutic potential (Kulkarni *et al.*, 2014; Kulkarni *et al.*, 2012). In this review, therefore, we summarise the literature describing sex differences in certain psychiatric disorders, and then probe whether these differences are due to the influence of selected steroid hormones. We outline the evidence of steroid hormone dysregulation in each disorder, emphasising the similarities across disorders.

The integral role of estradiol and progesterone in psychiatry is highlighted and a number of unanswered questions are posed as improvements for further studies are suggested.

This review will focus on schizophrenia, BD and PTSD, three sexually dimorphic psychiatric disorders that show similarities in clinical/cognitive symptomatology, aetiology and neurobiology. In the next section we detail evidence of sex differences in these three disorders, focussing on the differences between men and women in disease incidence, onset and symptom expression.

2. Sex differences in psychiatric disorders

2.1 Schizophrenia

Schizophrenia is a chronic disorder characterised by multiple symptom categories, including positive psychotic symptoms, negative symptoms, disordered thoughts/speech, and cognitive deficits (APA, 2013). Sex differences in schizophrenia are widely documented in the literature, reportedly affecting several domains including disease onset, course of illness, and symptom profiles (Gogos *et al.*, 2015; Ochoa *et al.*, 2012; Sun *et al.*, 2016). The incidence of schizophrenia is greater in men (1.4:1 male:female ratio) (McGrath *et al.*, 2004), who typically experience peak onset between the ages of 18-25, approximately 4 years earlier than women (Galderisi *et al.*, 2012; Hafner, 2003). Additionally, women uniquely exhibit a second surge of disease onset around 45-49 years, suggested to be attributed to the decline of ovarian hormones due to menopause (Hafner, 2003; Sun *et al.*, 2016). Sex differences in disease progression and prognosis have also been observed, with men showing less responsiveness to antipsychotic medication (Szymanski *et al.*, 1995), and longer, more frequent hospitalisations (Szymanski *et al.*, 1995; Usall *et al.*, 2003). Men also exhibit greater substance abuse (Koster *et al.*, 2008; Ochoa *et al.*, 2012), social isolation, and withdrawal than women (Koster *et al.*, 2008; Zhang *et al.*, 2012), who have better social prognoses, including retainment of marriages, interpersonal relationships (Hafner, 2003; Vila-Rodriguez *et al.*, 2011), and employment (Cotton *et al.*, 2009;

Vila-Rodriguez *et al.*, 2011). Furthermore, women experience higher rates of remission and recovery than men (Carpiniello *et al.*, 2012). Whilst the sex differences in schizophrenia are typically observed post-diagnosis, a recent review suggests their presence prior to the onset of clinically detectable symptoms, with men displaying poorer premorbid functioning than women, including greater social withdrawal, isolation, and poor self-care (Mendrek *et al.*, 2016).

In addition to the sex differences in social and behavioural domains, men with schizophrenia experience more brain morphological abnormalities than women. For example, gross anatomical studies show greater ventricular enlargement (Narr *et al.*, 2001), and more severe frontal and temporal lobe atrophy in men (Bryant *et al.*, 1999; Narr *et al.*, 2001). Furthermore, men also show greater abnormalities in white matter microstructure (Kanaan *et al.*, 2012; Kelly *et al.*, 2018).

Research regarding sex differences in symptomology in schizophrenia remains less clear. Some studies report that women suffer more positive (Thorup *et al.*, 2007) and affective symptoms than men (Ochoa *et al.*, 2012; Zhang *et al.*, 2012), and several studies suggest milder symptoms overall in women, including fewer cognitive deficits (Han *et al.*, 2012), and less severe negative symptoms (Bakhshi *et al.*, 2015; Galderisi *et al.*, 2012; Grossman *et al.*, 2008; Koster *et al.*, 2008). By contrast, others failed to identify any sex differences in positive or negative symptoms (Han *et al.*, 2012; Ochoa *et al.*, 2012; Szymanski *et al.*, 1995). Furthermore, both men (Morgan *et al.*, 2008) and women (Szymanski *et al.*, 1995) have been reported as suffering greater depressive symptoms, and women experience worse negative symptoms than men (Galderisi *et al.*, 2012). There are several possible explanations for these discrepancies, including inconsistent methodology, sampling variation and size, and the use of different symptom evaluation tools, particularly when comparing earlier versus recent studies. Sex-specific differences in comorbid and psychosocial factors including substance abuse (Riecher-Rössler *et al.*, 2018), and access to, or engagement with social supports may also explain some of the sex differences observed (Grossman *et al.*, 2008). These issues highlight the need for further investigation into sex differences using a systematic approach to control for confounding variables.

2.2 Bipolar Disorder

BD is a complex disorder characterised by extreme fluctuations in mood, from manic highs to depressive lows (APA, 2013). Two diagnostic subtypes are recognised; BD I – characterised by at least one episode of full blown mania that impacts functioning, or BD II – characterised by a more short-lived and less severe form of mania, called hypomania, that occurs alongside episodes of depression. The lifetime incidence of BD is approximately 1:1 in men and women, although the incidence of manic episodes and unipolar mania is higher in men with the disease (Diflorio *et al.*, 2010). Research suggests an increased prevalence of BD II and hypomania in women, with general functioning being significantly better for men with this BD subtype (Diflorio *et al.*, 2010). Women with BD also report increased rates of rapid cycling in some but not all studies (Baldassano *et al.*, 2005; Diflorio *et al.*, 2010; Robb *et al.*, 1998). Reports of sex differences in psychosis symptoms are inconsistent; with some studies finding an increased prevalence in men versus women (Morgan *et al.*, 2005) or vice-versa (Bräunig *et al.*, 2009), and others finding no differences at all (Kessing, 2004). Comorbid phobia, panic disorder, PTSD, eating disorders and borderline personality disorder are more frequently reported in women than men with BD, while higher rates of comorbid conduct and substance use disorders are reported in men (Diflorio *et al.*, 2010; Suominen *et al.*, 2009).

Most extant studies indicate an equivocal age of onset across the sexes, although some have reported that women may be slightly older than men when the disease manifest (Diflorio *et al.*, 2010; Kawa *et al.*, 2005; Robb *et al.*, 1998; Suppes *et al.*, 2001). Recurrent depressive polarity and a depressive or mixed onset has been shown to predominate in women with BD (Kessing, 2004; Viguera *et al.*, 2001), while mania may be more prevalent in men at first onset (Kawa *et al.*, 2005; Suppes *et al.*, 2001). Owing to inconsistent literature, it is not clear if there are sex differences in the *number* of depressive or manic episodes (Baldassano *et al.*, 2005; Diflorio *et al.*, 2010; Robb *et al.*, 1998). However, some studies do show an increased use of antidepressant

treatment in women with BD, as well as of benzodiazepines, electroconvulsive therapy and psychotherapy (Baldassano *et al.*, 2005; Karanti *et al.*, 2015). On the other hand, men appear to be treated with lithium more often (Karanti *et al.*, 2015), but sex differences in its clinical response are not evident (Viguera *et al.*, 2001). Women with BD have far increased rates of hypothyroidism (when lithium-treated) and are at increased risk of migraine, compared to men; while rates of metabolic syndrome appear to be equivocal across the sexes (Diflorio *et al.*, 2010; Saunders *et al.*, 2014).

Sex-specific effects on cognitive profiles have been largely unexplored in the BD literature. However, there is some evidence to show that men with BD perform worse on visuospatial construction (Gogos *et al.*, 2010) and better on spatial memory and sustained attention tasks (Bücker *et al.*, 2014) compared to women with BD but not controls. Men with BD have also been found to have worse verbal memory performance (Carrus *et al.*, 2010), worse recognition of happy prosody (Van Rheezen *et al.*, 2013) and reduced sensorimotor gating (Gogos *et al.*, 2009) compared to male controls; while worse recognition of surprise and fear prosody (Bozikas *et al.*, 2007) and increased sensorimotor gating (Gogos *et al.*, 2009) has been seen in women with BD compared to female controls. One study showed that women with BD experience greater cognitive benefit from vigorous physical activity than men with BD (Fellendorf *et al.*, 2017).

In terms of brain morphology, there is no evidence of sex differences in global grey or white matter, limbic, or ventricular and sulcal volumes (Jogia *et al.*, 2012). Reduced grey matter volume of the medial prefrontal cortex however, has been reported in men with BD compared to male controls (Almeida *et al.*, 2009; Jogia *et al.*, 2012). Further, right hippocampal volume loss is evident in women versus men with BD (Shi *et al.*, 2018) but not controls. Women with BD also exhibit abnormal neural engagement of the caudate and prefrontal cortex during social-cognitive tasks compared to female controls (Jogia *et al.*, 2012). Overall, compared to schizophrenia there is very little research investigating sex differences in BD. However, the

available data show that there are sex differences in a number of domains of BD, supporting the idea that sex is an important consideration in BD.

2.3 Post-Traumatic Stress Disorder

PTSD is a common disorder that occurs after experiencing a traumatic event involving threat to life or physical integrity (APA, 2013). It is characterised by re-experiencing symptoms including intrusive memories and nightmares of the trauma, avoidance of trauma reminders, hyper-arousal and dysregulation in mood, cognition and in the hypothalamic-pituitary axis (Pitman *et al.*, 2012). There are several known risk factors for PTSD, including previous psychiatric or trauma history, family psychiatric history, and age at trauma onset. One of the most robust known risk factors of PTSD is being female. Large scale epidemiological and prospective studies consistently report that women develop PTSD at approximately twice the rate of men following trauma (Christiansen *et al.*, 2015; Kessler *et al.*, 2017; Olf, 2017; Tolin *et al.*, 2006). Longitudinally, the PTSD sex difference is highest between the ages of 21 and 25, with men and women reporting their highest rates of PTSD in their 40s and 50s, respectively (Ditlevsen *et al.*, 2010).

Sex differences in the risk of PTSD are not attributable to measurement errors, reporting bias or methodological issues (Christiansen *et al.*, 2015; Tolin *et al.*, 2006). A multiplicity of factors (social, cognitive, biological and genetic) may contribute to this sex difference; for example, women are exposed to greater interpersonal and sexual violence, which lead to greater rates of PTSD (Christiansen *et al.*, 2015; Forbes *et al.*, 2014; Kessler *et al.*, 2017; Olf, 2017). In contrast, men are typically exposed to more industrial accidents, war and combat trauma and physical assaults (Kessler *et al.*, 2017). This raises the question, if women are associated with more toxic forms of trauma exposure such as sexual violence, might this explain their heightened risk of developing PTSD? The most definitive test of whether sex differences in PTSD can be attributed to sex differences in prevalence of exposure to different types of trauma was in the

largest study in a US sample of >34,000 participants (Blanco *et al.*, 2018). Lifetime prevalence for PTSD was 9.48% in women and 5.97% in men, and women experienced childhood maltreatment and assaultive violence more often than men. However, differences in the prevalence of exposure to varying trauma types did not explain the differential risk of PTSD in women and men. In fact, most types of trauma (17 out of 19) were associated with greater risk of PTSD in women than in men. A key finding of this study was that a difference in reactivity to trauma, regardless of the type of trauma, explained more than 60% of the differential PTSD risk in women and men (Blanco *et al.*, 2018).

In epidemiological studies, there are sex differences in initial reactivity to trauma with increased peri-traumatic dissociation and perception of life threat reported as more prevalent immediate responses in women than men (Bryant *et al.*, 2003; Irish *et al.*, 2011; Norris *et al.*, 2002; Solomon *et al.*, 2005). Differences in symptom presentation appear to dissipate somewhat over time, with studies reporting similar symptomology between men and women, albeit women reporting stronger intensity across all symptoms (Carragher *et al.*, 2016; Murphy *et al.*, 2018). There are few studies reporting sex differences in standard experimental tasks that assess PTSD mechanisms and risk factors. In one imaging study, however, increased blood-oxygen-level dependent (BOLD) activation was observed in the right amygdala and anterior cingulate cortex of healthy women compared to men during a fear conditioning task, a task where reduction in arousal to analogue trauma (e.g. electric shock) is measured physiologically (Lebron-Milad *et al.*, 2012). Further, we showed that women have greater negative memory consolidation than men in response to stress-induction, suggesting a potential mechanism for the greater female susceptibility to developing PTSD (Felmingham *et al.*, 2012c). In this study, participants viewed negative, neutral and positive images and were then exposed to a stress-induction test (i.e. cold-pressor stress task) immediately following encoding and stress hormones (cortisol and salivary alpha amylase) were recorded. Although women and men showed similar stress-induced increases in cortisol, women showed significantly greater recall of negative images which

suggests greater negative memory consolidation following stress in women (Felmingham *et al.*, 2012c).

Women appear to be more responsive to PTSD treatment than men, with studies reporting better treatment gains and maintenance to exposure and behavioural therapies in female patients (Felmingham *et al.*, 2012a; Galovski *et al.*, 2013; Stenmark *et al.*, 2014). Most recently, a meta-analysis of 48 of these studies confirmed that women indeed have better treatment responses than men, though this primarily examined studies employing behavioural interventions, and differences in responses to pharmacological treatment were not reported (Wade *et al.*, 2016). Interestingly, it is also reported that women with, but not without, PTSD express higher fear responses to a conditioned stimulus than men (Inslicht *et al.*, 2013), which may explain the success during exposure therapy, due to the reliance of the technique on effective reactivation of trauma memories. However, there has not been sufficient research to identify why treatment responses are better in women, with tentative explanations involving increased learning capacity in females during both trauma experience and extinction training (Felmingham *et al.*, 2012a).

3. Are gonadal steroid hormones the mediating factor?

The neurobiological complexity of the psychiatric disorders described above contributes to the fact that the exact mechanisms underlying the aetiology of these disorders remain elusive. However, the most commonly attributed candidate to explain the sex differences described above, is the dysfunction of neuroactive steroid systems (Gogos *et al.*, 2015; Sun *et al.*, 2016). For example, the above observations underpin the *estrogen hypothesis of schizophrenia*, which postulates a protective role of estrogens against the development and severity of the disorder (Gogos *et al.*, 2015; Seeman *et al.*, 1990). Similarly, in relation to PTSD, evidence of sex differences has led to the hypothesis that low estradiol results in poor extinction recall. The reproductive life cycle in women makes them particularly sensitive to rapid and/or cyclical variation in levels of circulating ovarian hormones at different time periods. In this section, we

briefly describe the two primary ovarian hormones and then detail evidence of gonadal steroid dysfunction in each of the psychiatric disorders of interest.

3.1 The main female steroid hormones: Estrogens and Progesterone

The ovarian hormones, estrogens and progesterone, are also neuroactive steroids which play a crucial role in glial and neuronal development, structure, and function (Barth *et al.*, 2015). Of these, progestogens are a class of neuroactive steroids that bind to, and activate progesterone receptors. In humans, endogenous progesterone (P4) is the most potent and abundant progestogen subtype. It is synthesised both centrally and peripherally via catalysis of [pregnenolone](#), a cholesterol-derived steroid precursor (Sun *et al.*, 2016; Tsutsui, 2008) (Figure 1). As a precursor to estrogens, [testosterone](#) (the main male gonadal hormone), and various glucocorticoids and mineralocorticoids, progesterone plays a crucial role in both male and female health and development. In adult males, serum progesterone levels reportedly range between 1-3 nM with little change relative to age (Oettel *et al.*, 2004; Sun *et al.*, 2016). In contrast, non-pregnant premenopausal women experience variable serum progesterone levels relative to their menstrual cycle (Figure 2), with lowest concentrations reported during the early follicular phase (0.3-2 nM) and maximum concentrations during the mid-luteal phase (20-55 nM) (Mumford *et al.*, 2010; Sun *et al.*, 2016). Progesterone levels are highest during pregnancy, with serum progesterone steadily increasing throughout the gestational period, and reaching peak concentrations of up to 4-fold non-pregnant levels at term (Byrns, 2014; Schock *et al.*, 2016). By contrast, serum progesterone levels dramatically decline following menopause (Santoro, 2005).

The term *estrogen* describes a class of structurally and functionally similar compounds, the most common of which are estrone (E1); 17 β estradiol, or ‘estradiol’ (E2); and estriol (E3) (Thomas *et*

al., 2013). Of these, estradiol is the most potent endogenous estrogen in humans (Gogos *et al.*, 2015; Jeyakumar *et al.*, 2011), and the focal estrogen of this review. The synthesis of estrogens occurs both centrally and peripherally, and is mediated via aromatisation of testosterone (Figure 1). Estradiol is present in both males and females, however adult males show considerably lower total serum estradiol than females (140 pM) (Sun *et al.*, 2016; Yamamoto *et al.*, 1995), with minimal fluctuations or age-related decline (Greenblatt *et al.*, 1976; Orwoll *et al.*, 2006). Conversely, non-pregnant premenopausal women exhibit biphasic cyclic variation in serum estradiol during their 28-day menstrual cycle (Figure 2); lowest estradiol levels during the early follicular phase (median ~150 pM), highest levels during ovulation (median ~670 pM), and a second, smaller peak during the mid-luteal phase (median ~500 pM) (Stricker *et al.*, 2006; Sun *et al.*, 2016). During pregnancy, estradiol levels increase up to 9-fold, but drop dramatically postpartum (Schock *et al.*, 2016). Similarly, estradiol levels decline dramatically following menopause, reaching levels ≤ 100 pM (Burger *et al.*, 1998).

Steroid hormones may work via either organisational or activational effects. Organisational mechanisms refer to the effects of steroid hormones during prenatal and early postnatal development that result in permanent effects on the brain. Whilst activational mechanisms are the receptor-mediated transient actions of steroid hormones that occur predominantly in adulthood. Throughout the brain, progesterone and estradiol function by directly binding to receptors that act via genomic and non-genomic mechanisms (Gogos *et al.*, 2015; Newton-Mann *et al.*, 2017; Petersen *et al.*, 2013). Of these, the most common of the genomic receptors are ligand-modulated transcription factors known as [progesterone receptor](#)-A and -B, and [estrogen receptor](#)- α and - β . Following the diffusion of the steroid hormone across the cellular membrane, it then activates its cytoplasmic receptor, triggering conformational changes that result in receptor homo- or hetero-dimerisation. The dimerised receptors then translocate to the nucleus where they bind to promoter regions of target genes and regulate transcription (Ellmann *et al.*, 2009). Dimerised estrogen receptors specifically bind to activator protein 1 sites or estrogen response elements, enabling transcription of estrogen-responsive genes (Newton-Mann *et al.*,

2017). The non-genomic effects of progesterone are primarily mediated via several membrane-bound receptors; estrogenic signalling also occurs via membrane-bound receptors, and G protein-coupled estrogen receptor 1. The non-genomic effects of these steroids are rapid and involve activation of a range of downstream effects (Newton-Mann *et al.*, 2017; Petersen *et al.*, 2013).

To summarise, in women, estradiol and progesterone levels fluctuate throughout the reproductive lifespan. Further, these levels are much higher in women than in men. Whilst progesterone primarily exerts its effects via activating its receptors, it also has significant indirect effects via its conversion into a number of neuroactive molecules, including testosterone and estrogens. This constant, complex interaction between steroid hormones needs to be recognised before one can consider the effects of hormones across the reproductive life cycle.

3.2 Evidence of gonadal steroid hormone dysregulation in Schizophrenia

Women with schizophrenia often experience symptom fluctuation relative to their menstrual cycle phase, and also experience high rates of irregular menses – a common symptom of gonadal hormone dysfunction (Gleeson *et al.*, 2016). Further, the cyclical exacerbation of symptoms corresponds to periods of low levels of estradiol and progesterone in the menstrual cycle (Bergemann *et al.*, 2007; Hoff *et al.*, 2001; Kumari *et al.*, 2010), during which times women also experience increased rates of hospitalisation (Bergemann *et al.*, 2002). Similarly, symptom improvements during pregnancy, and worsening of symptoms post-partum correspond to increased and decreased gonadal hormone levels, respectively (Riecher-Rössler, 2017). This is also true for the mid-life surge of female diagnoses, which correspond with menopause (Ochoa *et al.*, 2012), with women over the age of forty receiving new diagnoses at approximately twice the rate of men (Riecher-Rössler, 2017).

The above findings may be explained, at least in part, to chronic hypoestrogenism in schizophrenic patients. Low serum estradiol has been reported in both male (Belvederi Murri *et al.*, 2016; Doğan Bulut *et al.*, 2016) and female (Bergemann *et al.*, 2002; Bergemann *et al.*,

2007) patients with schizophrenia and first-episode psychosis with serum estradiol varying relative to menstrual phase in females. Women showed reduced estradiol levels throughout the entire menstrual cycle, with hypoestrogenism identified during the follicular phase (defined as serum estradiol below 110 pM), as well as the peri-ovulatory phase (defined as serum estradiol below 370 pM) (Bergemann *et al.*, 2005). It is important to note that these effects are thought to be unrelated to antipsychotic drug treatment-induced hyperprolactinemia, which can itself induce a hypoestrogenic state (McGregor *et al.*, 2017). Similarly, compared to healthy controls, lower serum progesterone has been reported in both male and female patients with schizophrenia (Bicikova *et al.*, 2013; Doğan Bulut *et al.*, 2016; Ritsner *et al.*, 2007). Antipsychotic medications were reported to significantly increase pregnenolone levels in the brain, suggesting that correction of aberrant progesterone signalling may be partially involved in their efficacy (Ritsner, 2011). A recent meta-analysis found elevated levels of circulating [dehydroepiandrosterone](#) sulphate (DHEA-S) and testosterone levels in both male and female patients with schizophrenia or first-episode psychosis (Misiak *et al.*, 2018). Numerous studies report a negative correlation between serum testosterone and the severity of negative symptoms and cognitive deficits in male patients with schizophrenia (Akhondzadeh *et al.*, 2006; Ko *et al.*, 2007; Shirayama *et al.*, 2002; Sisek-Sprem *et al.*, 2015). Whilst further research is needed, these findings suggest dysfunction at multiple levels of the neurosteroid biosynthetic pathway.

At present, research into the use of hormonal therapies in schizophrenia is providing promising results (reviewed in (Gogos *et al.*, 2015; Sbisa *et al.*, 2017)). Studies by Kulkarni and colleagues demonstrated that combined antipsychotic and estradiol therapy significantly improved symptoms in premenopausal female patients, particularly the positive symptoms, and improved general psychopathology in male patients, without causing feminising side-effects (reviewed in (Kulkarni *et al.*, 2012)). Similarly, a double-blind placebo-controlled trial found that combined administration of haloperidol and a synthetic estradiol significantly improved both positive and negative symptoms in premenopausal women with chronic schizophrenia (Akhondzadeh *et al.*, 2003). Unfortunately, long-term use of estradiol may be associated with side-effects including

increased cardiovascular and cancer risk (reviewed in (Sbisa *et al.*, 2017)). Additionally, the ligand-binding domains for estrogen receptor- α and - β are highly homologous (Newton-Mann *et al.*, 2017), making it difficult to selectively target these receptors using orthosteric ligands. In an attempt to subvert these issues, researchers are exploring the therapeutic potential of selective estrogen receptor modulators, such as [raloxifene](#), that elicit tissue-dependent and/or receptor-dependent agonist or antagonist effects (Sbisa *et al.*, 2017). While the exact mechanism of action of raloxifene in the CNS is unclear, it has high affinity for both estrogen receptor- α and - β (Newton-Mann *et al.*, 2017). However, depending on sex, reproductive status, and hormone levels, the clinical efficacy of raloxifene is likely to vary (Sbisa *et al.*, 2017). Nevertheless, reviews have concluded that combined antipsychotic and raloxifene therapy improves both positive and negative symptoms in women with schizophrenia, and improves negative symptoms in men with schizophrenia (Bratek *et al.*, 2016; McGregor *et al.*, 2017). In perimenopausal and postmenopausal women (aged 40-70 years) with treatment-resistant schizophrenia, raloxifene reduced symptom severity and improved likelihood of clinical response (Kulkarni *et al.*, 2016). By contrast, another study found that severely ill, postmenopausal women with schizophrenia receiving adjunct raloxifene did not show symptom improvement, and in fact experienced worsened positive and negative symptoms (Weiser *et al.*, 2017). The authors concluded that whilst raloxifene may be beneficial for some patients, further research is needed to identify suitable subgroups for safe administration.

Interestingly, one study found that adjunctive low-dose pregnenolone improved positive symptoms, extrapyramidal side effects, and several measures of executive function in chronically ill male and female patients (Ritsner, 2010). Furthermore, progesterone administration has been shown to improve cognition in healthy women (Berent-Spillson *et al.*, 2015) suggesting it may be of benefit for the cognitive deficits in schizophrenia. However, progesterone and its receptors have received considerably less attention than estradiol in the neuropsychiatric community, thus further research is needed to better understand the role of progesterone, as well as other neuroactive compounds, in schizophrenia (Sun *et al.*, 2016). Overall, there is strong evidence for

a role of steroid hormones in schizophrenia and in particular, that reduced estradiol levels may be a predisposing factor to disease development and symptom severity in at-risk populations.

3.3 Evidence of gonadal steroid hormone dysregulation in Bipolar Disorder

A large proportion of women with BD have menstrual abnormalities that precede diagnosis (Rasgon *et al.*, 2005). There are a number of studies providing evidence that reproductive life cycle events associated with hormonal fluctuations, specifically a reduction in hormone levels, can influence the course of BD. For example, perimenstrual mood changes are reported in 40-65% of BD women (Blehar *et al.*, 1998; Teatero *et al.*, 2014), and those women who experience perimenstrual mood changes are at higher risk for post-partum relapse (Perich *et al.*, 2017), a worse course of illness and increased symptom severity (Dias *et al.*, 2011). Rapid cycling, comorbid anxiety and mixed mood episodes, as well as an earlier age of mania or depression onset are also more frequently reported in BD women who have reported reproductive life cycle associated mood changes (Perich *et al.*, 2017). The luteal phase of the menstrual cycle (both early and late luteal, i.e. low hormone levels) has been associated with greater manic/depressive symptoms compared to other phases (Rasgon *et al.*, 2003; Shivakumar *et al.*, 2008). An elevation of mood and psychosis symptoms post-partum is common (Blehar *et al.*, 1998; Jones *et al.*, 2014), with one study reporting an 8-fold increase in the prevalence of mania symptoms in BD women in the week following childbirth compared to during pregnancy (Heron *et al.*, 2009). Some clinical studies also show high rates of emotional disturbance with an onset in pregnancy, although epidemiological studies indicate that the prevalence rate for first time hospitalisations for a mood episode during pregnancy is low (Jones *et al.*, 2014). The risk of BD relapse during the post-partum period is estimated at 35%, with higher relapse rates in women who are medication naïve during pregnancy compared to those that aren't (Wesseloo *et al.*, 2015). Notably, conversion from major depressive disorder to BD also appears to be several fold higher in the first six months post-partum than typically seen annually (Sharma *et al.*, 2014). Transition

to menopause is also commonly characterised by an increase in mood disturbance in women with BD (Blehar *et al.*, 1998; Marsh *et al.*, 2015). Longitudinal evidence indicates that progression from pre to postmenopausal stages is associated with a decrease in mood stability associated with increasing depressive and decreasing mania symptoms (Marsh *et al.*, 2012).

While this clinical evidence implicates fluctuations in gonadal hormones in the phenomenology of BD in women, research on gonadal hormone and neurosteroid profiles in the disorder is sparse. One study reported significantly decreased cerebrospinal fluid levels of pregnenolone in BD patients irrespective of sex, that was driven by patients who were depressed rather than euthymic at the time of testing (George *et al.*, 1994). Another study reported that relative to controls, euthymic BD women had increased circulating progesterone and [allopregnanolone](#) (active metabolite of progesterone) but not cortisol concentrations during the luteal phase of the menstrual cycle (Hardoy *et al.*, 2006). In contrast, two other studies found that the progesterone and estradiol levels of women with BD (either rapid cycling or with post-partum BD relapse) did not differ from control women during either the mid-luteal or follicular phases of the menstrual cycle (Karadag *et al.*, 2004; Wieck *et al.*, 2003). Finally, testosterone levels were lower in depressed men with BD, but higher in depressed women with BD, compared to their respective controls (Wooderson *et al.*, 2015). Higher testosterone levels during a depressive or mixed episode have been associated with an increased incidence of mania and suicide attempts in BD patients, irrespective of sex (Sher *et al.*, 2012), with baseline testosterone predictive of future suicidal behaviour in depressed or mixed episode BD women (Sher *et al.*, 2014).

Further evidence for the involvement of gonadal hormones in BD comes from studies where women were receiving exogenous estrogenic treatments. A small study reported that there were no significant mood changes in women with BD who were taking oral contraceptives (containing combined synthetic estradiol and progesterone) on the active versus inactive (placebo) days, but there was a slight but significant worsening of mood in BD women *not* taking oral contraceptives (first seven days of cycle versus last seven days) (Rasgon *et al.*, 2003). Several small clinical trials also highlight the efficacy of the selective estrogen receptor modulator, tamoxifen, and one

study showed benefits using the synthetic progesterone, medroxyprogesterone, for the treatment of acute mania (Kulkarni *et al.*, 2014; Meinhard *et al.*, 2014). In a study of women with postpartum psychosis and estrogen deficiency, psychosis symptoms were ameliorated with daily estradiol treatment (Ahokas *et al.*, 2000). Pregnenolone has also been shown to be efficacious for the treatment of BD depression, although the mechanism of action is unclear given that changes in depressive symptoms did not correlate with changes in serum pregnenolone or other neurosteroids (Brown *et al.*, 2014). The evidence for steroid hormone dysregulation in women with BD is supported by studies showing a worsening of symptoms during times of low levels of gonadal hormones, and by clinical trials suggesting that certain steroid hormones can improve specific symptoms of BD.

3.4 Evidence of gonadal steroid hormone dysregulation in Post-Traumatic Stress Disorder

Gonadal hormones are thought to be a critical factor in the contrasting rates of PTSD diagnoses between men and women (Ney *et al.*, 2018; Rasmusson *et al.*, 2017). Human studies have identified estradiol as an important regulator of the recall of extinction memories (Glover *et al.*, 2015), which is the quintessential process underlying recovery from a traumatic experience. This may be expected, given the known importance of estradiol on memory, learning and cognitive processes more generally (Frick *et al.*, 2015; Gogos *et al.*, 2014; Sbisà *et al.*, 2017). In studies of fear extinction in healthy women, it has been found that higher estradiol levels are associated with improved task performance, where participants learn that a previously aversive stimulus is no longer associated with an aversive experience (for example, an electric shock) with success gauged by change in physiological arousal upon presentation of the stimulus (Graham *et al.*, 2013; Milad *et al.*, 2010; Wegerer *et al.*, 2014; Zeidan *et al.*, 2011). Similar studies have found that women with higher levels of endogenous estradiol more successfully extinguish fear memories compared to women using hormonal contraceptives (Graham *et al.*, 2013; Li *et al.*, 2016; White *et al.*, 2016). The effect of menstrual cycle phase on fear extinction in healthy

women is less consistent, with a large scale study finding no significant differences between phases (Lonsdorf *et al.*, 2015).

Although no study has examined long-term estradiol levels in PTSD patients, there has been some research measuring gonadal hormones in PTSD. One study found that women with PTSD and low estradiol levels had intensified physiological responses to an aversive laboratory stimulus, compared to non-PTSD women with low estradiol levels. This effect was absent in women with high estradiol levels, where PTSD and non-PTSD participants displayed similar responding to the aversive stimulus, strongly suggesting a protective effect of estradiol on fear learning (Glover *et al.*, 2012). Women with PTSD were also shown to exhibit increased phobic anxiety and depression during the early follicular, compared to mid-luteal, phase of the menstrual cycle (Nillni *et al.*, 2015). In another study, women with PTSD in the mid-luteal phase of the menstrual cycle exhibited impaired fear extinction compared to women in the early follicular phase (Pineles *et al.*, 2016), which is the reverse finding of healthy participants. Whilst it is unclear what the mechanistic implications of these findings might be, recent genetic studies have identified estradiol-related risk factors for PTSD, with estrogen-response elements on the pituitary adenylate cyclase-activating peptide (PACAP) receptor gene, PAC1R, associated with PTSD severity in women but not men (Lind *et al.*, 2017). This is a significant finding since PACAP deficiency is associated with impaired production of transcriptional factors underlying both the HPA and sympathetic stress responses in mice (Stroth *et al.*, 2010). The recent meta-analysis by Lind and colleagues (2017) therefore provides evidence of hormone influences on stress reactivity at the genetic level, and a possible diverging factor in prevalence and severity of PTSD between the sexes. Further, estrogen-dependent effects on DNA methylation of on the HDAC4 gene may be associated with fear learning and memory in PTSD (Maddox *et al.*, 2018).

Whereas estrogenic signalling is implicated in effective recovery following a traumatic experience, consolidation of emotional memories may instead be associated with progesterone levels at the time of trauma. Studies of real-world trauma have shown that increased reports of flashback memories and increased PTSD symptomology are associated with hospitalisation

during the mid-luteal phase (Bryant *et al.*, 2011), which is characterised by peak progesterone levels as well as elevated estradiol. Similarly, survivors of sexual assault who neglected to take emergency contraception (which contains high dose progesterone) were significantly more likely to report higher PTSD symptomology compared to those who did take emergency contraception (Ferree *et al.*, 2012). In the laboratory, healthy women who are in the mid-luteal phase report more intrusive memories of negative stimuli (Ertman *et al.*, 2011; Wassell *et al.*, 2015), and this effect is correlated with levels of progesterone but not estradiol at encoding (Ertman *et al.*, 2011; Felmingham *et al.*, 2012b; Wassell *et al.*, 2015). Only one study has found that estradiol was associated with increased reports of intrusive memories (Cheung *et al.*, 2013); conversely another study found that estradiol was associated with decreased reports of intrusions (Wegerer *et al.*, 2014). Overall, a number of studies support a facilitative effect of progesterone levels on intrusive memories of emotionally negative stimuli during encoding, with inconsistent or negligible effects of estradiol.

4. Future directions and implications

The exact mechanisms underlying the sex differences in the severe psychiatric disorders described above are unclear, but likely involve genetic factors, biological, cognitive and social influences. In this review, we have focussed on the role of gonadal and neuroactive hormones, particularly estradiol and progesterone, to explain the sex differences. Whilst it is common for researchers to investigate the role of gonadal hormones in women, what about men? Estradiol and progesterone may also play an important role on symptom severity in men (Kulkarni *et al.*, 2013), conversely it may be that testosterone is the key hormone influencing disease development and severity in men (Ko *et al.*, 2007). Further, there is a strong link between testosterone and estrogens, whereby the enzyme aromatase regulates the conversion of testosterone to estradiol (Figure 1). The role of hormones in men is an important issue and yet an understudied area; again highlighting that future research should always consider both males and females.

Based on the evidence presented here, it is clear that female hormone variation informs similar symptom profiles across schizophrenia, BD, and PTSD. In both schizophrenia and BD, low levels of estradiol are associated with increased manic and psychotic-like symptoms, as demonstrated in both experimental and observational studies (Gogos *et al.*, 2015; Meinhard *et al.*, 2014). In PTSD, low estradiol levels are associated with poorer recovery following a traumatic experience and continuity of PTSD symptoms (Glover *et al.*, 2015), while progesterone levels may influence the consolidation of emotional memories at the time of trauma. In all of these disorders, higher estradiol is generally associated with improved symptomology; this is most relevant to the cognitive domain and represents a significant novel treatment avenue (Glover *et al.*, 2015; Gogos *et al.*, 2015; Meinhard *et al.*, 2014).

An intriguing contradiction between symptom profiles of these three disorders is that, despite high estradiol being recognised as a key protective factor explaining lower rates of schizophrenia and BD-II in women, low estradiol is conversely believed to drive higher prevalence of PTSD in women. Given that women have higher estradiol levels than men, were estradiol a primary aetiological protective factor in all three disorders it might have been expected that women would have lower, rather than higher, rates of PTSD as is observed in schizophrenia. This phenomenon is likely explainable by the differential influence of gonadal hormone fluctuation during different stages of PTSD. In PTSD, trauma causes an extreme biological stress response resulting in downregulation of the hypothalamic-pituitary-gonadal (HPG) axis and lower production of estradiol and progesterone that results in impaired extinction learning long-term (Ney *et al.*, 2018; Toufexis *et al.*, 2014). Restoration of these hormones in PTSD, and similarly upregulation in schizophrenia and BD, therefore appears to be a promising treatment option for similar reasons between the disorders, including through augmentation of cognition. However, high levels of gonadal hormones may similarly be a risk factor for PTSD through facilitation of learning, which acts to enhance consolidation of trauma memories at the time of trauma. The differential effect of hormones in this case reflects PTSD as a delayed disorder, characterised by an initial stressor and a later onset of symptomology (APA, 2013).

It is important to recognise that steroid hormones show dynamic interactions, meaning that treatment target options may include more than just estradiol. For example, in PTSD, downregulation of the HPG axis coincides with interruption of cortisol production in the hypothalamic-pituitary-adrenal (HPA) axis following extreme stress created during trauma (Ney *et al.*, 2018; Pitman *et al.*, 2012; Toufexis *et al.*, 2014). Restoration of either of these pathways can improve PTSD symptomology through the cognitive aspects of fear extinction learning (Glover *et al.*, 2015; Ney *et al.*, 2018; Pitman *et al.*, 2012). It is necessary to consider that these axes, as with all steroid hormone production, are inseparable and are dual effectors in disorders that are stress-related; not only in PTSD, but cortisol production is chronically dysregulated in both schizophrenia and BD (Girshkin *et al.*, 2014). Similarly, the effects attributed to estradiol and progesterone in each of these disorders might be better explained by the increasingly recognised influence of other neuroactive steroids (which include precursors and metabolites of estradiol and progesterone; Figure 1) in psychiatric disorders, such as pregnenolone, allopregnanolone, testosterone and DHEA (Melcangi *et al.*, 2011; Rasmusson *et al.*, 2017; Ritsner, 2011; Sun *et al.*, 2016; Zheng, 2009). For instance, research has highlighted the importance of allopregnanolone and DHEA for fear extinction learning and PTSD symptomology (Rasmusson *et al.*, 2017). Unlike progesterone, allopregnanolone is a potent allosteric modulator of the GABA-A receptor, a receptor implicated in psychiatric disorders (Melcangi *et al.*, 2011; Sun *et al.*, 2016). A recent study showed that men with psychotic features of schizophrenia, BD or major depression had elevated DHEA levels compared to those without a history of psychosis (Buoli *et al.*, 2016). Given the known interactions between neuroactive steroids, it is important to identify the underlying imbalances in steroid levels for each disorder. For example, in women, PTSD was associated with lower levels of 5 α -dihydroprogesterone, the primary metabolite of progesterone and precursor of allopregnanolone (Pineles *et al.*, 2018), suggesting that pharmacological targeting of 5 α -dihydroprogesterone, rather than allopregnanolone or progesterone, may be beneficial. Findings of an imbalance of various

neuroactive steroids in these psychiatric disorders underscores the importance of further research into steroid interactions instead of isolated targets such as estradiol.

Overall, this review provides compelling evidence for cross-disorder estradiol-related protective mechanisms, which may be expected given the known importance of both genomic and non-genomic effects of estrogens on cognitive processes more generally (Frick *et al.*, 2015). However, estradiol and progesterone have broad functional diversity in the brain, with both types of receptor implicated in multiple processes such as neurogenesis, microglia expression, inflammation, and bioenergetics (Gogos *et al.*, 2015; Rettberg *et al.*, 2014; Sun *et al.*, 2016). Given this diversity, it is unlikely that steroid hormones play a single role in the pathogenesis and pathophysiology of PTSD, schizophrenia, or BD – rather, their role is likely to regulate various signalling, neurodevelopmental, neuroplastic, and epigenetic processes. As an example, all three disorders are characterised by reductions in hippocampal volume and functioning (Lieberman *et al.*, 2018; Pitman *et al.*, 2012; Shi *et al.*, 2018), which is attributable to various neurobiological mechanisms associated with learning and memory. Estradiol has been shown to modulate phosphorylation of ERK, mTOR and PKA pathways (Fortress *et al.*, 2013; Hasegawa *et al.*, 2015; Kim *et al.*, 2016) and can increase dendritic spine density of hippocampal neurons (Luine *et al.*, 2013). Phosphorylation of these pathways in turn mediate estrogenic genomic actions including DNA methylation and histone acetylation in the hippocampus, subsequently affecting levels of proteins such as brain-derived neurotrophic factor (Zhao *et al.*, 2010), which is a potent effector of learning and memory and recognised as a critical factor in psychiatric disorders (Luine *et al.*, 2013; Pitman *et al.*, 2012; Wu *et al.*, 2013). Given the well-established role of neurotransmitter dysfunction in psychiatric disorders, it is important to note that both estradiol and progesterone modulate the activity of dopaminergic, serotonergic, glutamatergic and GABAergic systems (for example, (Kokras *et al.*, 2018); reviewed in (Barth *et al.*, 2015; Gogos *et al.*, 2015; Sun *et al.*, 2016)). Neurobiological pathways involved in the pathophysiology of these disorders, specifically the prefrontal and limbic networks and their connectivity, have also been shown to have sex specificity (Felmingham *et al.*, 2010). Estradiol

receptors are expressed throughout the hippocampus (Osterlund *et al.*, 2000), as well as the dorsolateral prefrontal cortex (Montague *et al.*, 2008), for which cross-talk is involved in increasing psychotic symptomology (Lieberman *et al.*, 2018) as well as being critical to fear circuitry (Pitman *et al.*, 2012). Based on this converging evidence, it is likely that the similarities in symptomology between these three disorders is attributed to dysfunction across similar estrogenic-mediated mechanisms. In support, the most recent clinical studies have detected large genome-wide association overlaps in heritability of vulnerability towards PTSD and schizophrenia, with a moderate shared effect between these disorders and BD (Duncan *et al.*, 2018). Future research will need to assess the extent to which similar mechanisms mediate symptomology across disorders and lessons may be learnt by combining methodologies and theoretical models between fields.

Finally, there are some common limitations across studies. Examining the specific effects of gonadal hormones in a naturalistic human setting is particularly difficult. Inconsistencies in the literature are likely due to varied methodologies in the population selection (e.g. women in different reproductive life stages), and the symptom/task/hormone measures (e.g. estimated cycle phase compared to blood levels or saliva assays). To compound this, the lack of methodological detail makes it very difficult to compare across studies. For example, when one discusses differences across the menstrual cycle, it is often unclear what the effects observed are actually due to – is it really a change in estradiol level? Or is it the accompanying increase in progesterone (Sun *et al.*, 2016) or testosterone levels that are the mediating factors? To complicate matters further, it is unknown whether the differences observed in blood hormone levels correspond to CNS hormone levels; therefore, using changes in blood levels as evidence for these hormones mediating the sex differences in psychiatric disorders should be treated with caution. Another issue is the increasing prevalence of hormonal contraceptive use by women; studies need to report on contraceptive use, including type of contraception, duration of use, and so on. This is particularly important given the known influence of contraceptives, containing synthetic estrogen and progestin, on cognition (Gogos *et al.*, 2014). Using animal models of

psychiatric disorders is one way we can control for many of the confounding variables (Gogos *et al.*, 2015; Sbisa *et al.*, 2017). Future studies require a more inclusive, considered effort of steroid hormones and the intricacies of the interactions between them, with methodological rigour applied, to enhance our understanding of the roles of steroid hormones in psychiatric disorders.

5. Conclusions

Psychiatric disorders such as schizophrenia, BD and PTSD are chronic and debilitating diseases that have no easy treatment and in some cases, they are incurable. Current medications are inadequate; they do not treat all patients of all symptoms, nor are they side-effect free. Thus, the need for the development of better treatments, or perhaps adjunctive treatments, is clearly important. Could gonadal hormones, such as estradiol, provide the framework for the development of future therapeutics? In this review, three different psychiatric disorders were examined, however, there are a number of similarities between them, such as cognitive impairment, genetic predisposition, neurotransmitter dysfunction, inflammation, and so on. It has been proposed that a mechanism uniting the genetic and neurobiological factors implicated in psychiatric disorders might be endocrine responses, specifically estradiol, which has been described as the 'master regulator' of these systems (Rettberg *et al.*, 2014). Given the fact that the steroid receptors are wide-spread throughout the CNS (Newton-Mann *et al.*, 2017), and that steroid hormones have wide-ranging effects on the CNS (Gogos *et al.*, 2015), it is not surprising that estradiol and progesterone can modulate the expression of psychiatric disorders. Although, whether the influence of steroid hormones requires organisational or activational effects or genomic or non-genomic actions is not clear, but likely involves a combination of these. One thing is obvious, there are marked sex differences across multiple disorders; women with schizophrenia tend to exhibit less disease impairment than men (Gogos *et al.*, 2015), but women with PTSD are more affected than men (Blanco *et al.*, 2018). We implore to researchers and clinicians to, at the very least, acknowledge that sex differences exist. Thus future studies should be balanced for sex, and in the clinic, women may need to be classified according to their

hormone status before starting treatment. Illuminating the extent to which steroid hormones facilitate these purported sex differences, and the associated mechanisms, may lead to avenues for novel therapeutic approaches, and allow for precision medicine for men as well as women. This has important potential therapeutic implications for the preponderance of neuropsychiatric diseases with sexually dimorphic incidence, symptomology and treatment responses.




Figure 1: Simplified biosynthesis pathway for progesterone and estradiol.

HSD: hydroxysteroid dehydrogenase P450: cytochrome P450; P450scc: cholesterol side-chain cleavage enzyme; (adapted from Sun *et al.*, 2016).




Figure 2: Fluctuating circulating levels of 17β -estradiol and progesterone in women across the menstrual cycle (adapted from (Sun *et al.*, 2016; Widmaier *et al.*, 2014)).

Nomenclature of Targets and Ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding *et al.*, 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander *et al.*, 2017).

Acknowledgements

We gratefully acknowledge the financial support of the National Health and Medical Research Council of Australia (AG CDF ID1108098; TVR ECF ID1088785; KLF program grant APP1073041). The Florey Institute of Neuroscience and Mental Health acknowledges the

support from the Victorian Government's Operational Infrastructure Support Grant. TVR has received funding from the Helen McPherson Smith Trust, Swinburne University of Technology, University of Melbourne, Society of Mental Health Research, Rebecca L. Cooper Foundation, Jack Brockhoff Foundation, CASS Foundation, Ian Potter Foundation, and the Henry Freeman Trust.

Competing Interests

None

Did not involve animal experimentation, does not include Western blots or immunohistochemistry

Declaration of transparency and scientific rigour

This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research as stated in the *BJP* guidelines for [Design & Analysis](#), and as recommended by funding agencies, publishers and other organisations engaged with supporting research.

References

Ahokas A, Aito M, Rimón R (2000). Positive treatment effect of estradiol in postpartum psychosis: a pilot study. *The Journal of clinical psychiatry* **61**(3): 166-169.

Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L, *et al.* (2003). Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. *Prog Neuropsychopharmacol Biol Psychiatry* **27**(6): 1007-1012.

Akhondzadeh S, Rezaei F, Larijani B, Nejatisafa AA, Kashani L, Abbasi SH (2006). Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. *Schizophr Res* **84**(2-3): 405-410.

Alexander SP, Cidlowski JA, Kelly E, Marrion NV, Peters JA, Harding SD, *et al.* THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors. *Br J Pharmacol* 2017; 174 Suppl 1: S208-S224.

Almeida JR, Akkal D, Hassel S, Travis MJ, Banihashemi L, Kerr N, *et al.* (2009). Reduced gray matter volume in ventral prefrontal cortex but not amygdala in bipolar disorder: significant effects of gender and trait anxiety. *Psychiatry Research: Neuroimaging* **171**(1): 54-68.

APA (2013). *Diagnostic and Statistical Manual of Mental Disorders. 5th Edition.* edn. American Psychiatric Association: Washington D.C., USA.

Bakhshi K, Chance SA (2015). The neuropathology of schizophrenia: A selective review of past studies and emerging themes in brain structure and cytoarchitecture. *Neuroscience* **303**: 82-102.

Baldassano CF, Marangell LB, Gyulai L, Nassir Ghaemi S, Joffe H, Kim DR, *et al.* (2005). Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. *Bipolar Disorders* **7**(5): 465-470.

Barth C, Villringer A, Sacher J (2015). Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. *Frontiers in Neuroscience* **9**: 37.

Belvederi Murri M, Fanelli F, Pagotto U, Bonora E, Triolo F, Chiri L, *et al.* (2016). Neuroactive Steroids in First-Episode Psychosis: A Role for Progesterone? *Schizophrenia research and treatment* **2016**: 1942828.

Berent-Spillson A, Briceno E, Pinsky A, Simmen A, Persad CC, Zubieta JK, *et al.* (2015). Distinct cognitive effects of estrogen and progesterone in menopausal women. *Psychoneuroendocrinology* **59**: 25-36.

Bergemann N, Mundt C, Parzer P, Jannakos I, Nagl I, Salbach B, *et al.* (2005). Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. *Schizophr Res* **73**(2-3): 357-366.

Bergemann N, Parzer P, Nagl I, Salbach B, Runnebaum B, Mundt C, *et al.* (2002). Acute psychiatric admission and menstrual cycle phase in women with schizophrenia. *Archives of women's mental health* **5**(3): 119-126.

Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C (2007). Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. *Psychol Med* **37**(10): 1427-1436.

Bicikova M, Hill M, Ripova D, Mohr P, Hampl R (2013). Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. *J Steroid Biochem Mol Biol* **133**: 77-83.

Blanco C, Hoertel N, Wall MM, Franco S, Peyre H, Neria Y, *et al.* (2018). Toward Understanding Sex Differences in the Prevalence of Posttraumatic Stress Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry* **79**(2).

Blehar MC, DePaulo Jr JR, Gershon ES, Reich T (1998). Women with bipolar disorder: findings from the NIMH Genetics Initiative sample. *Psychopharmacology Bulletin* **34**(3): 239.

Bozikas VP, Kosmidis MH, Tonia T, Andreou C, Focas K, Karavatos A (2007). Impaired Perception of Affective Prosody in Remitted Patients With Bipolar Disorder. *Journal of Neuropsychiatry and Clinical Neurosciences* **19**(4): 436-440.

Bratek A, Krysta K, Drzyzga K, Baranska J, Kucia K (2016). The role of selective estrogen receptor modulators in the treatment of schizophrenia. *Psychiatria Danubina* **28**(Suppl-1): 45-48.

Bräunig P, Sarkar R, Effenberger S, Schoofs N, Krüger S (2009). Gender differences in psychotic bipolar mania. *Gender medicine* **6**(2): 356-361.

Brown ES, Park J, Marx CE, Hynan LS, Gardner C, Davila D, *et al.* (2014). A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. *Neuropsychopharmacology* **39**(12): 2867.

Bryant NL, Buchanan RW, Vladar K, Breier A, Rothman M (1999). Gender differences in temporal lobe structures of patients with schizophrenia: a volumetric MRI study. *Am J Psychiatry* **156**(4): 603-609.

Bryant RA, Felmingham KL, Silove D, Creamer M, O'Donnell M, McFarlane AC (2011). The association between menstrual cycle and traumatic memories. *J Affect Disord* **131**(1-3): 398-401.

Bryant RA, Harvey AG (2003). Gender differences in the relationship between acute stress disorder and posttraumatic stress disorder following motor vehicle accidents. *The Australian and New Zealand journal of psychiatry* **37**(2): 226-229.

Bücker J, Popuri S, Muralidharan K, Kozicky J-M, Baitz HA, Honer WG, *et al.* (2014). Sex differences in cognitive functioning in patients with bipolar disorder who recently recovered from a first episode of mania: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). *Journal of Affective Disorders* **155**: 162-168.

Buoli M, Caldiroli A, Serati M, Grassi S, Altamura AC (2016). Sex Steroids and Major Psychoses: Which Role for DHEA-S and Progesterone. *Neuropsychobiology* **73**(3): 178-183.

Burger HG, Cahir N, Robertson DM, Groome NP, Dudley E, Green A, *et al.* (1998). Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. *Clinical endocrinology* **48**(6): 809-813.

Byrns MC (2014). Regulation of progesterone signaling during pregnancy: Implications for the use of progestins for the prevention of preterm birth. *The Journal of Steroid Biochemistry and Molecular Biology* **139**: 173-181.

Carpiniello B, Pinna F, Tusconi M, Zaccheddu E, Fatteri F (2012). Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study. *Schizophrenia research and treatment* **2012**: 576369.

Carragher N, Sunderland M, Batterham PJ, Calear AL, Elhai JD, Chapman C, *et al.* (2016). Discriminant validity and gender differences in DSM-5 posttraumatic stress disorder symptoms. *Journal of Affective Disorders* **190**: 56-67.

Carrus D, Christodoulou T, Hadjulis M, Haldane M, Galea A, Koukopoulos A, *et al.* (2010). Gender differences in immediate memory in bipolar disorder. *Psychological Medicine* **40**(8): 1349-1355.

Cheung J, Chervovsky L, Felmingham KL, Bryant RA (2013). The role of estrogen in intrusive memories. *Neurobiol Learn Mem* **106**: 87-94.

Christiansen DM, Hansen M (2015). Accounting for sex differences in PTSD: A multi-variable mediation model. *Eur J Psychotraumatol* **6**: 26068.

Cotton SM, Lambert M, Schimmelmann BG, Foley DL, Morley KI, McGorry PD, *et al.* (2009). Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. *Schizophr Res* **114**(1-3): 17-24.

Dias RS, Lafer B, Russo C, Del Debbio A, Nierenberg AA, Sachs GS, *et al.* (2011). Longitudinal Follow-Up of Bipolar Disorder in Women With Premenstrual Exacerbation: Findings From STEP-BD. *American Journal of Psychiatry* **168**(4): 386-394.

Diflorio A, Jones I (2010). Is sex important? Gender differences in bipolar disorder. *International Review of Psychiatry* **22**(5): 437-452.

Ditlevsen DN, Elklit A (2010). The combined effect of gender and age on post traumatic stress disorder: do men and women show differences in the lifespan distribution of the disorder? *Annals of General Psychiatry* **9**: 32-32.

Doğan Bulut S, Bulut S, Güriz O (2016). The relationship between sex hormone profiles and symptoms of schizophrenia in men. *Comprehensive psychiatry* **69**: 186-192.

Duncan LE, Ratanatharathorn A, Aiello AE, Almli LM, Amstadter AB, Ashley-Koch AE, *et al.* (2018). Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex differences in heritability. *Mol Psychiatry* **23**(3): 666-673.

Ellmann S, Sticht H, Thiel F, Beckmann MW, Strick R, Strissel PL (2009). Estrogen and progesterone receptors: from molecular structures to clinical targets. *Cell Mol Life Sci* **66**(15): 2405-2426.

Ertman N, Andreano JM, Cahill L (2011). Progesterone at encoding predicts subsequent emotional memory. *Learn Mem* **18**(12): 759-763.

Fellendorf FT, Kainzbauer N, Platzer M, Dalkner N, Bengesser SA, Birner A, *et al.* (2017). Gender differences in the association between physical activity and cognitive function in individuals with bipolar disorder. *Journal of Affective Disorders* **221**: 232-237.

Felmingham K, Williams LM, Kemp AH, Liddell B, Falconer E, Peduto A, *et al.* (2010). Neural responses to masked fear faces: sex differences and trauma exposure in posttraumatic stress disorder. *J Abnorm Psychol* **119**(1): 241-247.

Felmingham KL, Bryant RA (2012a). Gender differences in the maintenance of response to cognitive behavior therapy for posttraumatic stress disorder. *J Consult Clin Psychol* **80**(2): 196-200.

Felmingham KL, Fong WC, Bryant RA (2012b). The impact of progesterone on memory consolidation of threatening images in women. *Psychoneuroendocrinology* **37**(11): 1896-1900.

Felmingham KL, Tran TP, Fong WC, Bryant RA (2012c). Sex differences in emotional memory consolidation: the effect of stress-induced salivary alpha-amylase and cortisol. *Biol Psychol* **89**(3): 539-544.

Ferree NK, Wheeler M, Cahill L (2012). The influence of emergency contraception on post-traumatic stress symptoms following sexual assault. *J Forensic Nurs* **8**(3): 122-130.

Forbes D, Lockwood E, Phelps A, Wade D, Creamer M, Bryant RA, *et al.* (2014). Trauma at the Hands of Another: Distinguishing PTSD Patterns Following Intimate and Nonintimate Interpersonal and Noninterpersonal Trauma in a Nationally Representative Sample. *Journal of Clinical Psychiatry* **75**(2): 147-153.

Fortress AM, Fan L, Orr PT, Zhao Z, Frick KM (2013). Estradiol-induced object recognition memory consolidation is dependent on activation of mTOR signaling in the dorsal hippocampus. *Learn Mem* **20**(3): 147-155.

Frick KM, Kim J, Tuscher JJ, Fortress AM (2015). Sex steroid hormones matter for learning and memory: estrogenic regulation of hippocampal function in male and female rodents. *Learn Mem* **22**(9): 472-493.

Galderisi S, Bucci P, Ucok A, Peuskens J (2012). No gender differences in social outcome in patients suffering from schizophrenia. *Eur Psychiatry* **27**(6): 406-408.

Galovski TE, Blain LM, Chappuis C, Fletcher T (2013). Sex differences in recovery from PTSD in male and female interpersonal assault survivors. *Behaviour research and therapy* **51**(6): 247-255.

George MS, Guidotti A, Rubinow D, Pan B, Mikalaukas K, Post RM (1994). CSF neuroactive steroids in affective disorders: Pregnenolone, progesterone, and DBI. *Biological Psychiatry* **35**(10): 775-780.

Girshkin L, Matheson SL, Shepherd AM, Green MJ (2014). Morning cortisol levels in schizophrenia and bipolar disorder: a meta-analysis. *Psychoneuroendocrinology* **49**: 187-206.

Gleeson PC, Worsley R, Gavrilidis E, Nathoo S, Ng E, Lee S, *et al.* (2016). Menstrual cycle characteristics in women with persistent schizophrenia. *The Australian and New Zealand journal of psychiatry* **50**(5): 481-487.

Glover EM, Jovanovic T, Mercer KB, Kerley K, Bradley B, Ressler KJ, *et al.* (2012). Estrogen levels are associated with extinction deficits in women with posttraumatic stress disorder. *Biol Psychiatry* **72**(1): 19-24.

Glover EM, Jovanovic T, Norrholm SD (2015). Estrogen and extinction of fear memories: implications for posttraumatic stress disorder treatment. *Biol Psychiatry* **78**(3): 178-185.

Gogos A, Joshua N, Rossell SL (2010). Use of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to investigate group and gender differences in schizophrenia and bipolar disorder. *Australian and New Zealand Journal of Psychiatry* **44**: 220-229.

Gogos A, Sbisa AM, Sun J, Gibbons A, Udawela M, Dean B (2015). A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings. *Int J Endocrinol* **2015**: 615356.

Gogos A, van den Buuse M, Rossell S (2009). Gender differences in prepulse inhibition (PPI) in bipolar disorder: Men have reduced PPI, women have increased PPI. *International Journal of Neuropsychopharmacology* **12**(9): 1249-1259.

Gogos A, Wu YC, Williams AS, Byrne LK (2014). The effects of ethinylestradiol and progestins ("the pill") on cognitive function in pre-menopausal women. *Neurochem Res* **39**(12): 2288-2300.

Graham BM, Milad MR (2013). Blockade of estrogen by hormonal contraceptives impairs fear extinction in female rats and women. *Biol Psychiatry* **73**(4): 371-378.

Greenblatt RB, Oettinger M, Bohler Clorinda SS (1976). Estrogen-Androgen Levels in Aging Men and Women: Therapeutic Considerations*. *Journal of the American Geriatrics Society* **24**(4): 173-178.

Grossman LS, Harrow M, Rosen C, Faull R, Strauss GP (2008). Sex Differences in Schizophrenia and Other Psychotic Disorders: A 20-Year Longitudinal Study of Psychosis and Recovery. *Comprehensive psychiatry* **49**(6): 523-529.

Hafner H (2003). Gender differences in schizophrenia. *Psychoneuroendocrinology* **28 Suppl 2**: 17-54.

Hammond R, Mauk R, Ninaci D, Nelson D, Gibbs RB (2009). Chronic treatment with estrogen receptor agonists restores acquisition of a spatial learning task in young ovariectomized rats. *Hormones and behavior* **56**(3): 309-314.

Han M, Huang XF, Chen DC, Xiu MH, Hui L, Liu H, *et al.* (2012). Gender differences in cognitive function of patients with chronic schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* **39**(2): 358-363.

Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S *et al.* (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. *Nucl Acids Res* **46**: D1091-D1106.

Hardoy MC, Serra M, Carta MG, Contu P, Pisu MG, Biggio G (2006). Increased neuroactive steroid concentrations in women with bipolar disorder or major depressive disorder. *Journal of Clinical Psychopharmacology* **26**(4): 379-384.

Hasegawa Y, Hojo Y, Kojima H, Ikeda M, Hotta K, Sato R, *et al.* (2015). Estradiol rapidly modulates synaptic plasticity of hippocampal neurons: Involvement of kinase networks. *Brain Res* **1621**: 147-161.

Heron J, Haque S, Oyebode F, Craddock N, Jones I (2009). A longitudinal study of hypomania and depression symptoms in pregnancy and the postpartum period. *Bipolar Disorders* **11**(4): 410-417.

Hoff AL, Kremen WS, Wieneke MH, Lauriello J, Blankfeld HM, Faustman WO, *et al.* (2001). Association of estrogen levels with neuropsychological performance in women with schizophrenia. *Am J Psychiatry* **158**(7): 1134-1139.

Inslicht SS, Metzler TJ, Garcia NM, Pineles SL, Milad MR, Orr SP, *et al.* (2013). Sex differences in fear conditioning in posttraumatic stress disorder. *J Psychiatr Res* **47**(1): 64-71.

Irish LA, Fischer B, Fallon W, Spoonster E, Sledjeski EM, Delahanty DL (2011). Gender Differences in PTSD Symptoms: An Exploration of Peritraumatic Mechanisms. *Journal of anxiety disorders* **25**(2): 209-216.

Jeyakumar M, Carlson KE, Gunther JR, Katzenellenbogen JA (2011). Exploration of dimensions of estrogen potency: parsing ligand binding and coactivator binding affinities. *J Biol Chem* **286**(15): 12971-12982.

Jogia J, Dima D, Frangou S (2012). Sex differences in bipolar disorder: a review of neuroimaging findings and new evidence. *Bipolar Disorders* **14**(4): 461-471.

Jones I, Chandra PS, Dazzan P, Howard LM (2014). Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. *The Lancet* **384**(9956): 1789-1799.

Kanaan RA, Allin M, Picchioni M, Barker GJ, Daly E, Shergill SS, *et al.* (2012). Gender differences in white matter microstructure. *PLoS One* **7**(6): e38272.

Karadag F, Akdeniz F, Erten E, Pirildar S, Yucel B, Polat A, *et al.* (2004). Menstrually related symptom changes in women with treatment-responsive bipolar disorder. *Bipolar Disorders* **6**(3): 253-259.

Karanti A, Bobeck C, Osterman M, Kardell M, Tidemalm D, Runeson B, *et al.* (2015). Gender differences in the treatment of patients with bipolar disorder: A study of 7354 patients. *Journal of Affective Disorders* **174**: 303-309.

Kawa I, Carter Janet D, Joyce Peter R, Doughty Caroline J, Frampton Chris M, Elisabeth Wells J, *et al.* (2005). Gender differences in bipolar disorder: age of onset, course, comorbidity, and symptom presentation. *Bipolar Disorders* **7**(2): 119-125.

Kelly S, Jahanshad N, Zalesky A, Kochunov P, Agartz I, Alloza C, *et al.* (2018). Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. *Mol Psychiatry* **23**(5): 1261-1269.

Kessing LV (2004). Gender differences in the phenomenology of bipolar disorder. *Bipolar Disorders* **6**(5): 421-425.

Kessler RC, Aguilar-Gaxiola S, Alonso J, Benjet C, Bromet EJ, Cardoso G, *et al.* (2017). Trauma and PTSD in the WHO World Mental Health Surveys. *European Journal of Psychotraumatology* **8**.

Kim J, Szinte JS, Boulware MI, Frick KM (2016). 17beta-Estradiol and Agonism of G-protein-Coupled Estrogen Receptor Enhance Hippocampal Memory via Different Cell-Signaling Mechanisms. *J Neurosci* **36**(11): 3309-3321.

Ko YH, Jung SW, Joe SH, Lee CH, Jung HG, Jung IK, *et al.* (2007). Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia. *Psychoneuroendocrinology* **32**(4): 385-391.

Kokras N, Pastrovas N, Papisava D, de Bournonville C, Cornil CA, Dalla C (2018). Sex differences in behavioral and neurochemical effects of gonadectomy and aromatase inhibition in rats. *Psychoneuroendocrinology* **87**: 93-107.

Koster A, Lajer M, Lindhardt A, Rosenbaum B (2008). Gender differences in first episode psychosis. *Soc Psychiatry Psychiatr Epidemiol* **43**(12): 940-946.

Kulkarni J, Berk M, Wang W, Mu L, Scarr E, Van Rheenen TE, *et al.* (2014). A Four Week Randomized Control Trial of Medroxyprogesterone, and Tamoxifen in Women with Mania *Psychoneuroendocrinology* **43**: 52-61.

Kulkarni J, Gavrilidis E, Gwini SM, Worsley R, Grigg J, Warren A, *et al.* (2016). Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial. *JAMA Psychiatry* **73**(9): 947-954.

Kulkarni J, Gavrilidis E, Worsley R, Hayes E (2012). Role of estrogen treatment in the management of schizophrenia. *CNS drugs* **26**(7): 549-557.

Kulkarni J, Gavrilidis E, Worsley R, Van Rheenen T, Hayes E (2013). The Role of Estrogen in the Treatment of Men with Schizophrenia. *International Journal of Endocrinology and Metabolism* **11**(3): 129-136.

Kumari V, Konstantinou J, Papadopoulos A, Aasen I, Poon L, Halari R, *et al.* (2010). Evidence for a role of progesterone in menstrual cycle-related variability in prepulse inhibition in healthy young women. *Neuropsychopharmacology* **35**(4): 929-937.

Lebron-Milad K, Abbs B, Milad MR, Linnman C, Rougemont-Bucking A, Zeidan MA, *et al.* (2012). Sex differences in the neurobiology of fear conditioning and extinction: a preliminary

fMRI study of shared sex differences with stress-arousal circuitry. *Biol Mood Anxiety Disord* **2**: 7.

Li S, Graham BM (2016). Estradiol is associated with altered cognitive and physiological responses during fear conditioning and extinction in healthy and spider phobic women. *Behav Neurosci* **130**(6): 614-623.

Lieberman JA, Girgis RR, Brucato G, Moore H, Provenzano F, Kegeles L, *et al.* (2018). Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. *Mol Psychiatry*.

Lind MJ, Marraccini ME, Sheerin CM, Bountress K, Bacanu SA, Amstadter AB, *et al.* (2017). Association of Posttraumatic Stress Disorder With rs2267735 in the ADCYAP1R1 Gene: A Meta-Analysis. *J Trauma Stress* **30**(4): 389-398.

Lonsdorf TB, Haaker J, Schumann D, Sommer T, Bayer J, Brassens S, *et al.* (2015). Sex differences in conditioned stimulus discrimination during context-dependent fear learning and its retrieval in humans: the role of biological sex, contraceptives and menstrual cycle phases. *Journal of Psychiatry and Neuroscience* **40**(6): 368-375.

Luine V, Frankfurt M (2013). Interactions between estradiol, BDNF and dendritic spines in promoting memory. *Neuroscience* **239**: 34-45.

Maddox SA, Kilaru V, Shin J, Jovanovic T, Almli LM, Dias BG, *et al.* (2018). Estrogen-dependent association of HDAC4 with fear in female mice and women with PTSD. *Mol Psychiatry* **23**(3): 658-665.

Marsh WK, Gershenson B, Rothschild AJ (2015). Symptom severity of bipolar disorder during the menopausal transition. *International Journal of Bipolar Disorders* **3**(1): 17.

Marsh WK, Ketter TA, Crawford SL, Johnson JV, Kroll-Desrosiers AR, Rothschild AJ (2012). Progression of female reproductive stages associated with bipolar illness exacerbation. *Bipolar Disorders* **14**(5): 515-526.

McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D (2004). A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. *BMC Med* **2**: 13.

McGregor C, Riordan A, Thornton J (2017). Estrogens and the cognitive symptoms of schizophrenia: Possible neuroprotective mechanisms. *Front Neuroendocrinol* **47**: 19-33.

Meinhard N, Kessing LV, Vinberg M (2014). The role of estrogen in bipolar disorder, a review. *Nord J Psychiatry* **68**(2): 81-87.

Melcangi RC, Panzica G, Garcia-Segura LM (2011). Neuroactive steroids: focus on human brain. *Neuroscience* **191**: 1-5.

Mendrek A, Mancini-Marie A (2016). Sex/gender differences in the brain and cognition in schizophrenia. *Neurosci Biobehav Rev* **67**: 57-78.

Milad MR, Zeidan MA, Contero A, Pitman RK, Klibanski A, Rauch SL, *et al.* (2010). The influence of gonadal hormones on conditioned fear extinction in healthy humans. *Neuroscience* **168**(3): 652-658.

Misiak B, Frydecka D, Loska O, Moustafa AA, Samochowiec J, Kasznia J, *et al.* (2018). Testosterone, DHEA and DHEA-S in patients with schizophrenia: A systematic review and meta-analysis. *Psychoneuroendocrinology* **89**: 92-102.

Montague D, Weickert CS, Tomaskovic-Crook E, Rothmond DA, Kleinman JE, Rubinow DR (2008). Oestrogen receptor alpha localisation in the prefrontal cortex of three mammalian species. *J Neuroendocrinol* **20**(7): 893-903.

Morgan VA, Castle DJ, Jablensky AV (2008). Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian National Study of Low Prevalence (Psychotic) Disorders. *The Australian and New Zealand journal of psychiatry* **42**(1): 74-82.

Morgan VA, Mitchell PB, Jablensky AV (2005). The epidemiology of bipolar disorder: sociodemographic, disability and service utilization data from the Australian National Study of Low Prevalence (Psychotic) Disorders. *Bipolar Disorders* **7**(4): 326-337.

Mumford SL, Schisterman EF, Siega-Riz AM, Browne RW, Gaskins AJ, Trevisan M, *et al.* (2010). A longitudinal study of serum lipoproteins in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study. *J Clin Endocrinol Metab* **95**(9): E80-85.

Murphy S, Elklit A, Chen YY, Ghazali SR, Shevlin M (2018). Sex differences in PTSD symptoms: A differential item functioning approach. *Psychological trauma : theory, research, practice and policy*.

Narr KL, Thompson PM, Sharma T, Moussai J, Blanton R, Anvar B, *et al.* (2001). Three-dimensional mapping of temporo-limbic regions and the lateral ventricles in schizophrenia: gender effects. *Biol Psychiatry* **50**(2): 84-97.

Newton-Mann E, Finney C, Purves-Tyson T, Gogos A (2017). Estrogen Receptors: Mechanism of Action and Relevance to Schizophrenia. *Curr Psychiatry Rev* **13**(1): 55-64.

Ney LJ, Matthews A, Bruno R, Felmingam KL (2018). Modulation of the endocannabinoid system by sex hormones: Implications for Posttraumatic Stress Disorder. *Neurosci Biobehav Rev*.

Nillni YI, Pineles SL, Patton SC, Rouse MH, Sawyer AT, Rasmusson AM (2015). Menstrual cycle effects on psychological symptoms in women with PTSD. *J Trauma Stress* **28**(1): 1-7.

Norris FH, Foster JD, Weisshaar DL (2002). *The epidemiology of sex differences in PTSD across developmental, societal, and research contexts*. edn.

Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J (2012). Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. *Schizophrenia research and treatment* **2012**: 916198.

Oettel M, Mukhopadhyay AK (2004). Progesterone: the forgotten hormone in men? *The aging male : the official journal of the International Society for the Study of the Aging Male* **7**(3): 236-257.

Olf M (2017). Sex and gender differences in post-traumatic stress disorder: an update. *European Journal of Psychotraumatology* **8**.

Orwoll E, Lambert LC, Marshall LM, Phipps K, Blank J, Barrett-Connor E, *et al.* (2006). Testosterone and Estradiol among Older Men. *The Journal of Clinical Endocrinology & Metabolism* **91**(4): 1336-1344.

Osterlund MK, Gustafsson J-Ak, Keller E, Hurd YL (2000). Estrogen Receptor β (ER β) Messenger Ribonucleic Acid (mRNA) Expression within the Human Forebrain: Distinct Distribution Pattern to ER α mRNA1. *The Journal of Clinical Endocrinology & Metabolism* **85**(10): 3840-3846.

Perich TA, Roberts G, Frankland A, Sinbandhit C, Meade T, Austin M-P, *et al.* (2017). Clinical characteristics of women with reproductive cycle-associated bipolar disorder symptoms. *Australian and New Zealand Journal of Psychiatry* **51**(2): 161-167.

Petersen SL, Intlekofer KA, Moura-Conlon PJ, Brewer DN, Del Pino Sans J, Lopez JA (2013). Novel progesterone receptors: neural localization and possible functions. *Frontiers in Neuroscience* **7**: 164.

Pinares-Garcia P, Stratikopoulos M, Zagato A, Loke H, Lee J (2018). Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders. *Brain sciences* **8**(8).

Pineles SL, Nillni YI, King MW, Patton SC, Bauer MR, Mostoufi SM, *et al.* (2016). Extinction retention and the menstrual cycle: Different associations for women with posttraumatic stress disorder. *J Abnorm Psychol* **125**(3): 349-355.

Pineles SL, Nillni YI, Pinna G, Irvine J, Webb A, Arditte Hall KA, *et al.* (2018). PTSD in women is associated with a block in conversion of progesterone to the GABAergic neurosteroids allopregnanolone and pregnanolone measured in plasma. *Psychoneuroendocrinology* **93**: 133-141.

Pitman RK, Rasmusson AM, Koenen KC, Shin LM, Orr SP, Gilbertson MW, *et al.* (2012). Biological studies of post-traumatic stress disorder. *Nat Rev Neurosci* **13**(11): 769-787.

Rasgon N, Bauer M, Glenn T, Elman S, Whybrow Peter C (2003). Menstrual cycle related mood changes in women with bipolar disorder. *Bipolar Disorders* **5**(1): 48-52.

Rasgon NL, Altshuler LL, Fairbanks L, Elman S, Bitran J, Labarca R, *et al.* (2005). Reproductive function and risk for PCOS in women treated for bipolar disorder. *Bipolar Disorders* **7**(3): 246-259.

Rasmusson AM, Marx CE, Pineles SL, Locci A, Scioli-Salter ER, Nillni YI, *et al.* (2017). Neuroactive steroids and PTSD treatment. *Neurosci Lett* **649**: 156-163.

Rettberg JR, Yao J, Brinton RD (2014). Estrogen: a master regulator of bioenergetic systems in the brain and body. *Front Neuroendocrinol* **35**(1): 8-30.

Riecher-Rössler A (2017). Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. *The Lancet Psychiatry* **4**(1): 63-72.

Riecher-Rössler A, Butler S, Kulkarni J (2018). Sex and gender differences in schizophrenic psychoses—a critical review. *Archives of women's mental health*.

Ritsner M, Maayan R, Gibel A, Weizman A (2007). Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. *Eur Neuropsychopharmacol* **17**(5): 358-365.

Ritsner MS (2011). The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia. *Neuroscience* **191**: 91-100.

Ritsner MS (2010). Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials. *CNS Neurosci Ther* **16**(1): 32-44.

Robb JC, Young LT, Cooke RG, Joffe RT (1998). Gender differences in patients with bipolar disorder influence outcome in the medical outcomes survey (SF-20) subscale scores. *Journal of Affective Disorders* **49**: 189-193.

Sanchez MG, Bourque M, Morissette M, Di Paolo T (2010). Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. *CNS Neurosci Ther* **16**(3): e43-71.

Santoro N (2005). The menopausal transition. *The American Journal of Medicine* **118**(12): 1405.

Saunders EF, Nazir R, Kamali M, Ryan KA, Evans S, Langenecker S, *et al.* (2014). Gender differences, clinical correlates and longitudinal outcome of bipolar disorder with co-morbid migraine. *The Journal of clinical psychiatry* **75**(5): 512.

Sbisa AM, van den Buuse M, Gogos A (2017). The effect of estradiol and its analogues on cognition in preclinical and clinical research: relevance to schizophrenia. In: Gargiulo PA, Mesones-Arroyo HL (eds). *Psychiatry and Neuroscience Update: Bridging the Divide*. Vol. 2: Springer. pp355-374.

Schock H, Zeleniuch-Jacquotte A, Lundin E, Grankvist K, Lakso HA, Idahl A, *et al.* (2016). Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. *BMC pregnancy and childbirth* **16**(1): 146.

Seeman MV, Lang M (1990). The role of estrogens in schizophrenia gender differences. *Schizophr Bull* **16**(2): 185-194.

Sharma V, Xie B, Campbell MK, Penava D, Hampson E, Mazmanian D, *et al.* (2014). A prospective study of diagnostic conversion of major depressive disorder to bipolar disorder in pregnancy and postpartum. *Bipolar Disorders* **16**(1): 16-21.

Sher L, Grunebaum MF, Sullivan GM, Burke AK, Cooper TB, Mann JJ, *et al.* (2014). Association of testosterone levels and future suicide attempts in females with bipolar disorder. *Journal of Affective Disorders* **166**: 98-102.

Sher L, Grunebaum MF, Sullivan GM, Burke AK, Cooper TB, Mann JJ, *et al.* (2012). Testosterone levels in suicide attempters with bipolar disorder. *Journal of Psychiatric Research* **46**(10): 1267-1271.

Shi J, Guo H, Fan F, Fan H, An H, Wang Z, *et al.* (2018). Sex differences of hippocampal structure in bipolar disorder. *Psychiatry Research: Neuroimaging* **273**: 35-41.

Shirayama Y, Hashimoto K, Suzuki Y, Higuchi T (2002). Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. *Schizophr Res* **58**(1): 69-74.

Shivakumar G, Bernstein IH, Suppes T, Network aTSFB (2008). Are Bipolar Mood Symptoms Affected by the Phase of the Menstrual Cycle? *Journal of Women's Health* **17**(3): 473-478.

Sisek-Sprem M, Krizaj A, Jukic V, Milosevic M, Petrovic Z, Herceg M (2015). Testosterone levels and clinical features of schizophrenia with emphasis on negative symptoms and aggression. *Nord J Psychiatry* **69**(2): 102-109.

Solomon Z, Gelkopf M, Bleich A (2005). Is terror gender-blind? Gender differences in reaction to terror events. *Soc Psychiatry Psychiatr Epidemiol* **40**(12): 947-954.

Stenmark H, Guzey IC, Elbert T, Holen A (2014). Gender and offender status predicting treatment success in refugees and asylum seekers with PTSD. *European Journal of Psychotraumatology* **5**: 10.3402/ejpt.v3405.20803.

Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P (2006). Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. *Clinical chemistry and laboratory medicine* **44**(7): 883-887.

Stroth N, Eiden LE (2010). Stress hormone synthesis in mouse hypothalamus and adrenal gland triggered by restraint is dependent on pituitary adenylate cyclase-activating polypeptide signaling. *Neuroscience* **165**(4): 1025-1030.

Sun J, Walker AJ, Dean B, van den Buuse M, Gogos A (2016). Progesterone: The neglected hormone in schizophrenia? A focus on progesterone-dopamine interactions. *Psychoneuroendocrinology* **74**: 126-140.

Suominen K, Mantere O, Valtonen H, Arvilommi P, Leppämäki S, Isometsä E (2009). Gender differences in bipolar disorder type I and II. *Acta Psychiatrica Scandinavica* **120**(6): 464-473.

Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL, *et al.* (2001). The Stanley Foundation Bipolar Treatment Outcome Network: II. demographics and illness characteristics of the first 261 patients. *Journal of Affective Disorders* **67**(1): 45-59.

Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, *et al.* (1995). Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. *Am J Psychiatry* **152**(5): 698-703.

Teatero ML, Mazmanian D, Sharma V (2014). Effects of the menstrual cycle on bipolar disorder. *Bipolar Disorders* **16**(1): 22-36.

Thomas MP, Potter BV (2013). The structural biology of oestrogen metabolism. *J Steroid Biochem Mol Biol* **137**: 27-49.

Thorup A, Petersen L, Jeppesen P, Ohlenschlaeger J, Christensen T, Krarup G, *et al.* (2007). Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline in the Danish OPUS study. *J Nerv Ment Dis* **195**(5): 396-405.

Tolin DF, Foa EB (2006). Sex differences in trauma and posttraumatic stress disorder: a quantitative review of 25 years of research. *Psychol Bull* **132**(6): 959-992.

Toufexis D, Rivarola MA, Lara H, Viau V (2014). Stress and the reproductive axis. *J Neuroendocrinol* **26**(9): 573-586.

Tsutsui K (2008). Progesterone biosynthesis and action in the developing neuron. *Endocrinology* **149**(6): 2757-2761.

Usall J, Ochoa S, Araya S, Marquez M, Group N (2003). Gender differences and outcome in schizophrenia: a 2-year follow-up study in a large community sample. *Eur Psychiatry* **18**(6): 282-284.

Van Rheenen TE, Rossell SL (2013). Auditory-prosodic processing in bipolar disorder; from sensory perception to emotion. *Journal of Affective Disorders* **151**(3): 1102-1107.

Viguera AC, Baldessarini RJ, Tondo L (2001). Response to lithium maintenance treatment in bipolar disorders: comparison of women and men. *Bipolar Disorders* **3**(5): 245-252.

Vila-Rodriguez F, Ochoa S, Autonell J, Usall J, Haro JM (2011). Complex interaction between symptoms, social factors, and gender in social functioning in a community-dwelling sample of schizophrenia. *The Psychiatric quarterly* **82**(4): 261-274.

Wade D, Varker T, Kartal D, Hetrick S, O'Donnell M, Forbes D (2016). Gender difference in outcomes following trauma-focused interventions for posttraumatic stress disorder: Systematic review and meta-analysis. *Psychological trauma : theory, research, practice and policy* **8**(3): 356-364.

Wassell J, Rogers S, Felmingham KL, Pearson J, Bryant RA (2015). Progesterone and mental imagery interactively predict emotional memories. *Psychoneuroendocrinology* **51**: 1-10.

Wegerer M, Kerschbaum H, Blechert J, Wilhelm FH (2014). Low levels of estradiol are associated with elevated conditioned responding during fear extinction and with intrusive memories in daily life. *Neurobiology of Learning and Memory* **116**: 145-154.

Weiser M, Levi L, Burshtein S, Hagin M, Matei VP, Podea D, *et al.* (2017). Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial. *J Clin Psychiatry* **78**(7): e758-e765.

Wesseloo R, Kamperman AM, Munk-Olsen T, Pop VJ, Kushner SA, Bergink V (2015). Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. *American Journal of Psychiatry* **173**(2): 117-127.

White EC, Graham BM (2016). Estradiol levels in women predict skin conductance response but not valence and expectancy ratings in conditioned fear extinction. *Neurobiol Learn Mem* **134 Pt B**: 339-348.

Widmaier EP, Raff H, Strang KT (2014). *Vander's Human Physiology: The Mechanisms of Body Function*. 13th Edition. McGraw Hill: New York.

Wieck A, Davies R, Hirst A, Brown N, Papadopoulos A, Marks M, *et al.* (2003). Menstrual cycle effects on hypothalamic dopamine receptor function in women with a history of puerperal bipolar disorder. *Journal of Psychopharmacology* **17**(2): 204-209.

Wooderson SC, Gallagher P, Watson S, Young AH (2015). An exploration of testosterone levels in patients with bipolar disorder. *BJPsych Open* **1**(2): 136-138.

Wu YC, Hill RA, Gogos A, van den Buuse M (2013). Sex differences and the role of estrogen in animal models of schizophrenia: interaction with BDNF. *Neuroscience* **239**: 67-83.

Yamamoto M, Hibi H, Katsuno S, Miyake K (1995). Serum Estradiol Levels in Normal Men and Men With Idiopathic Infertility. *International Journal of Urology* **2**(1): 44-46.

Zeidan MA, Igoe SA, Linnman C, Vitalo A, Levine JB, Klibanski A, *et al.* (2011). Estradiol modulates medial prefrontal cortex and amygdala activity during fear extinction in women and female rats. *Biol Psychiatry* **70**(10): 920-927.

Zhang XY, Chen DC, Xiu MH, Yang FD, Haile CN, Kosten TA, *et al.* (2012). Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. *J Clin Psychiatry* **73**(7): 1025-1033.

Zhao Z, Fan L, Frick KM (2010). Epigenetic alterations regulate estradiol-induced enhancement of memory consolidation. *Proc Natl Acad Sci U S A* **107**(12): 5605-5610.

Zheng P (2009). Neuroactive steroid regulation of neurotransmitter release in the CNS: Action, mechanism and possible significance. *Progress in Neurobiology* **89**: 134-152.

Table 1. Converged sex and hormone-related effects across disorders

	Schizophrenia	Bipolar Disorder	Post-traumatic Stress Disorder
Differences at the level of sex			
Incidence	M > F	M > F Type I M < F Type II	M < F
Age of onset	M < F	M < F #	Unknown
Symptom severity	M > F	F = M, depending on BD type	M < F
Symptom presentation	M > F for comorbid issues	M > F for mania M < F for depression	M < F for dissociation and threat sense
Treatment response	M < F for response to treatment, remission, recovery	Unknown	M < F for response to treatment
Interactions and effects of gonadal steroid hormones			
Blood estradiol levels	↓ in M and F	Mixed/inconclusive	Unknown
Blood progesterone levels	↓ in M and F	Mixed/inconclusive	↓ in F
Menstrual cycle effects	↑ symptoms during low-hormone phases	↑ symptoms during low-hormone phases	↑ symptoms during low-hormone phases#
Effects of menopause	↑ symptoms, prevalence	↑ depression and ↓ mania	Unknown
Effects of exogenous estradiol	Estradiol and raloxifene improved symptoms in M and F	Estradiol improved manic and psychotic symptoms	Estradiol improved performance in analogue trauma tasks in non-PTSD subjects

Note: M = Male, F = Female, < = less or worse, > = greater or better, ↑ = increased, ↓ = decreased, # = preliminary or weaker evidence.

List of Hyperlinks for Crosschecking

Supporting Information for Online Publication only

Estradiol <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013>

Progesterone <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377>

Progesterone receptor

<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627>

Estrogen receptors <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=96>

Pregnenolone <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2376>


Testosterone <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2858>

Raloxifene <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2820>

Allopregnanolone <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108>


Dehydroepiandrosterone

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2370>



BPH_14584_f1.jpg

Author Manuscript



BPH_14584_f2.jpg